Meridian Bioscience has entered into a group purchasing agreement under which it will supply its illumigene C difficile and illumigene Group B Streptococcus molecular tests to Premier Healthcare Alliance.
Under the agreement, Premier members will take advantage of special pricing negotiated for C difficile and Group B Streptococcus tests and instruments.
The illumigene molecular system uses loop-mediated isothermal DNA amplification (LAMP) technology and relies upon a simple procedure that includes heat treatment, amplification and detection.
The test procedure yields results in less than one hour and the entire amplification is isothermal and results are read on the illumipro-10 instrument.
Meridian Bioscience chief commercial officer Richard Eberly said: "We are privileged to collaborate with the Premier healthcare alliance to assist Premier members in their efforts to improve the quality of patient care and drive costs out of their facilities."